Global Clinical Specialist
An open-label, multi-center, prospective clinical trial was performed among 78 PCR-confirmed COVID-19 patients admitted to the ICU with severe or life-threatening symptoms. Convalescent plasma therapy combined with standard treatment (n = 28) was compared to standard treatment alone (n = 50), stratified by disease severity.
In combination with standard treatment, CP therapy resulted in 78% reduction of 28-day ICU mortality (HR = 0.22) compared to standard treatment alone. Also, other significant indicators of the treatment effect of CP show that this novel CP production method was effective and represents a practical solution for low and middle-income countries to produce CP locally.
HemoClear B.V. received CE Mark approval for its first-in-class, technology, the HemoClearTM autologous blood filter
As a proud sponsor, HemoClear is attending the 28th Nigerian Society of Anaesthetists Annual Scientific Conference. Dr Rosita Bihariesingh has been at the
HemoClear attends the Bloodless Medicine & Surgery Society 2020 Annual Scientific Conference. Our Chief Medical Officer, Dr Arno Nierich, will present